Journal of Clinical Oncology
Articles in this Issue
Comprehensive evaluation of immunotherapy combination approaches versus tyrosine-kinase inhibitor monotherapy for the treatment of hepatocellular carcinoma: A meta-analysis.
574 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and first-line tre...
Impact of pathological complete response after DCF neoadjuvant chemotherapy followed by surgery on survival in esophageal squamous cell carcinoma: A supplementary analysis of JCOG 1109.
457 Background: JCOG1109, a multicenter three-arm phase III trial, evaluated three neoadjuvant treatment regimens for adva...
Phase 1 study of LB1908, an autologous claudin 18.2-targeted CAR-T cell product, in subjects with advanced gastroesophageal adenocarcinoma.
374 Background: CLDN18.2 is a therapeutic target on gastric, gastroesophageal, and esophageal adenocarcinomas (GC/GEJC/EC)...
Determinants of biomarker testing and treatment selection by oncologists caring for patients (pts) with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AC).
453 Background: Biomarker testing helps guide targeted therapy in G/GEJ AC; however, with no standardized approach, treatm...
Glucagon-like peptide 1 receptor agonists and the risk of developing malignancies of the liver.
525 Background: Type 2 diabetes mellitus (T2DM) is associated with elevated risk of hepatocellular carcinoma. Insulin use...
Efficacy and safety of lirafugratinib in <i>FGFRi</i> -naïve cholangiocarcinoma (CCA) patients harboring <i>FGFR2</i> fusions/rearrangements ( <i>FGFR2</i> f/r).
476 Background: Outcomes remain poor for patients with advanced/metastatic CCA treated with first-line gemcitabine-cisplat...
Impact of smoking on immunotherapy outcomes in gastric, gastro-esophageal junction, and esophageal cancers (G/GEJ/EC): A real-world analysis.
320 Background: Outcomes of G/GEJ/EC remain poor despite the recent addition of immunotherapy (IO) to a chemotherapy backb...
Safety run-in results from C-SOLVE (JACCRO GC-12): A randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in patients with HER2-negative, CLDN18.2-positive unresectable advanced gastric or GEJ cancer.
352 Background: C-SOLVE (JACCRO GC-12; jRCTs031240510) is an ongoing randomized, non-comparative phase II trial investigat...
Identification of pleiotropic genetic risk variants for pancreatic cancer and diabetes.
692 Background: Pancreatic cancer (PC) is a deadly disease most often caught in late stages. Because there is a lack of ef...
Impact of sarcopenia on short- and long-term outcomes after multimodal therapy for esophageal cancer.
334 Background: Sarcopenia, or decreased skeletal muscle mass, has been associated with worse surgical and oncologic outco...
Emerging radiation paradigms: Utilization and survival outcomes of brachytherapy vs EBRT in pancreatic cancer—An NCDB analysis (2004–2020).
727 Background: Pancreatic cancer is the third leading cause of cancer mortality in the U.S. and remains among the deadlie...
Definitive SBRT in unresectable pancreatic cancer: Long-term outcomes with moderate vs high dose approaches.
677 Background: Locally advanced pancreatic cancer (LAPC) represents a substantial clinical challenge. Chemotherapy (CT) r...
Rural-urban disparities in pancreatic cancer mortality hotspots in the United States.
661 Background: Pancreatic Cancer is the sixth deadliest cancer across the world, and its incidence has more than doubled...
Phase I study of fulvestrant in combination with <sup>177</sup> Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
TPS649 Background: Peptide receptor radionuclide therapy (PRRT), using 177 Lu-DOTA...
A novel framework to grade the quality of surrogate endpoints at the trial level: An analysis of surrogate endpoints used in colorectal cancer trials.
41 Background: Surrogate endpoints of overall survival (OS) are increasingly used as the basis of cancer drug approvals, b...
Predictive and prognostic role of protease-activated receptors (PARs) in colorectal cancer (CRC).
213 Background: Protease-activated receptors (PARs) are G-protein-coupled receptors activated by thrombin and tissue facto...
KANDLELIT-012: Phase 3 study of MK-1084 (a <i>KRAS G12C</i> inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for <i>KRAS</i> <i>G12C</i> -mutant colorectal cancer.
TPS267 Background: KRAS G12C is an oncogenic driver mutation observed in 3-4% of m...
Care delivery among patients with early-onset versus average-onset cholangiocarcinoma: A nationwide retrospective analysis.
487 Background: While most patients with cholangiocarcinoma (CCA) belong to older age groups (≥65 years), the incidence of...
Patient and physician preferences for third-line or later (3L+) treatments of metastatic colorectal cancer (mCRC).
61 Background: When considering later-line treatments for mCRC, patients and physicians balance survival gains with advers...
Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite stable/proficient mismatch repair metastatic colorectal cancer: Updated survival analysis and safety outcomes from a multicenter, single-arm, phase 2 study (SYLT-026).
121 Background: This study evaluated the efficacy and safety of combining cadonilimab with FOLFIRINOX (irinotecan, oxalipl...
Obesity-associated colorectal cancer and the association with chemokine signaling and tumor remodeling pathways.
194 Background: Obesity is a known risk factor for colorectal cancer (CRC) that promotes systemic inflammation and T-cell...
Emergency department diagnosis and guideline concordant care in gastric cancer.
300 Background: Roughly half of new cases of gastric cancer are diagnosed in the Emergency Department (ED-dx). Patients wi...
Use of claims-based machine learning to assign pancreatic cancer stage for enhanced outcomes research in Medicare.
676 Background: Administrative claims are a rich source of data on real-world oncology costs, patient journeys, and treatm...
Young-onset colorectal cancer (YOCRC) in the nationwide precision oncology trial IMPRESS-Norway.
149 Background: YOCRC, defined as CRC diagnosis before age 50, is rising globally. Driving causes remain incompletely unde...
Perioperative FLOT in gastric cancer: Effect on survival among East Asian patients in a Canadian population-based cohort.
419 Background: The FLOT regimen has emerged as the standard perioperative chemotherapy for resectable gastric and gastroe...